YM BioSciences USA Cleared By US FDA To Initiate Phase II Clinical Trial Of Nimotuzumab In Children With Inoperable, Recurrent Brain Cancer
Aug 31st 2007Drug InformationCancer
YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, announced that its wholly-owned US subsidiary, YM BioSciences USA Inc. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
